drugset / Trial / NCT07377175
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.
Phase 1
Recruiting
76 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabShulan (Hangzhou) Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects
Timeline
- Start
- 2025-08-28
- Primary completion
- 2026-02-13
- Completion
- 2026-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BSY001 | Unknown | 37.5 mg | — |
| Subject | BSY001 | Unknown | 75 mg | — |
| Subject | BSY001 | Unknown | 150 mg | — |
| Subject | BSY001 | Unknown | 200 mg | — |
| Subject | BSY001 | Unknown | 300 mg | — |